Using this strategy, Kuo et al. designed the albumin-binding PSMA targeting agent [177Lu]Lu-HTK03149 (Glu replaced with Aad), resulting in significantly higher tumor uptake (145% higher absorbed dose) than [177Lu]Lu-PSMA-617, along with lower uptake in salivary glands (0.23 vs 1.78 %IA/g) and kidneys (79.7 vs 7.67%IA/g) at 1h post-injection 57. Here, FOLH1 is linked to neoplasm.